Amazon, Berkshire Hathaway, JPMorgan health venture names a CTO

Serkan Kutan has been appointed chief technology officer to the healthcare joint venture between Amazon, Berkshire Hathaway and JPMorgan Chase & Co. The venture, still unnamed, was formed at the start of 2018.

Kutan called the role his “dream job” in a LinkedIn post. Prior to joining the venture, he was CTO of Zocdoc, a digital booking platform for the healthcare industry. He also previously served as principal engineer/architect of the eCommerce platform for Amazon and as vice president/architect for technology infrastructure at Goldman Sachs.

The hiring comes at a time when details about the venture have started to leak, though the scale of what the three companies hope to achieve is still mostly unknown. In recent court documents that became available over a lawsuit from UnitedHealthcare to block the hiring of a former employee, the venture noted it plans to tackle healthcare costs and needs for employees of the three companies only.

The healthcare entity has also ramped up hiring of executives and other positions over the last several months.

Beyond hiring the CTO, the venture is also hiring for other positions, Kutan noted.

“The challenging task will require the best technology team in health care,” he wrote, while directing readers to a link with open jobs.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.